Translations:GLP-1 receptor agonist/4/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
FuzzyBot (talk | contribs)
Importing a new version from external source
 
(No difference)

Latest revision as of 21:59, 5 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (GLP-1 receptor agonist)
==Mechanism of action==
GLP-1 agonists work by activating the [[GLP-1 receptor]]. They slow [[gastric emptying]], inhibit the release of [[glucagon]], and stimulate [[insulin]] production, therefore reducing hyperglycemia in people with [[type 2 diabetes]]. They also reduce food intake and therefore body weight, making them an effective treatment for obesity. Another class of anti-diabetes drugs, the [[dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitors]], work by reducing the breakdown of endogenous GLP-1, and are generally considered less potent than GLP-1 agonists. Some of the metabolic effects of GLP-1 agonists in rodents are mediated via increased synthesis of fibroblast growth factor 21 ([[FGF21]]). Dual GLP-1/FGF21 receptor agonists have been developed by pharmaceutical companies.

Mechanism of action

GLP-1 agonists work by activating the GLP-1 receptor. They slow gastric emptying, inhibit the release of glucagon, and stimulate insulin production, therefore reducing hyperglycemia in people with type 2 diabetes. They also reduce food intake and therefore body weight, making them an effective treatment for obesity. Another class of anti-diabetes drugs, the DPP-4 inhibitors, work by reducing the breakdown of endogenous GLP-1, and are generally considered less potent than GLP-1 agonists. Some of the metabolic effects of GLP-1 agonists in rodents are mediated via increased synthesis of fibroblast growth factor 21 (FGF21). Dual GLP-1/FGF21 receptor agonists have been developed by pharmaceutical companies.